MYBL2 epitope peptides and vaccines containing the same

A technology of vaccines and amino acids, which is applied in the field of drugs for the treatment and prevention of tumors, and can solve problems such as low objective response rate

Inactive Publication Date: 2011-07-06
ONCOTHERAPY SCI INC
View PDF20 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, only low objective response rates have been observed so far in these cancer vaccine trials (Belli F et al., J Clin Oncol 2002 Oct 15, 20(20):4169-80; Coulie PG et al., Immunol Rev 2002 Oct, 188:33-42; Rosenberg SA et al., Nat Med 2004 Sep, 10(9):909-15)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MYBL2 epitope peptides and vaccines containing the same
  • MYBL2 epitope peptides and vaccines containing the same
  • MYBL2 epitope peptides and vaccines containing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0156] Materials and methods

[0157] cell line

[0158] A24 lymphoblastoid cell line (A24LCL) cells were established by transforming Epstein-Bar virus into HLA-A24 positive human B lymphocytes.

[0159] Selection of candidates for MYBL2-derived peptides

[0160] MYBL2-derived HLA-A*2402-binding 9- and 10-mer peptides were predicted using the binding prediction software "BIMAS" (http: / / www-bimas.cit.nih.gov / molbio / hla_bind), which It is described in Parker KC et al. J Immunol 1994, 152(1): 163-75 and Kuzushima K et al. Blood 2001, 98(6): 1872-81. The peptides were synthesized by Sigma (Sapporo, Japan) following standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethyl sulfoxide (DMSO) at 20 mg / ml and stored at -80C.

[0161] In vitro CTL induction

[0162...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from MYBL2 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the MYBL2 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and / or prophylaxis of (i.e., preventing) cancers (tumors), and / or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the MYBL2 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, testicular tumor, pancreatic cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer and esophageal cancer.

Description

technical field [0001] This application claims the benefit of US Provisional Application No. 61 / 060,293, filed June 10, 2008, the entire contents of which are hereby incorporated by reference. [0002] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides that are extremely effective as cancer vaccines, and drugs for treating and preventing tumors. Background of the invention [0003] It has been demonstrated that CD8-positive CTLs can recognize tumor-associated antigen (TAA)-derived epitope peptides appearing on major histocompatibility complex (MHC) class I molecules, and then kill tumor cells. Since the discovery of the first example of TAA—the melanoma antigen (MAGE) family, people have mainly used immunological methods (Boon T, Int J Cancer 1993 May 8, 54(2): 177-80; Boon T & van der Bruggen P, J Exp Med 1996 Mar 1, 183(3):725-9) have discover...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06
CPCA61K38/00C07K14/4702A61P35/00A61P37/04A61B10/00A61K38/02A61K38/08A61K39/00C07K7/06C12N5/10C12N5/12
Inventor 角田卓也大泽龙司
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap